The World Health Organizations recommended
albendazole or
mebendazole for treatment. utilizes "community diagnosis" (a survey is conducted on a population sample to decide about the need of intervention) instead of "individual diagnosis," which would be much more expensive than the treatment itself. Mass deworming allows for the treatment of large number of infected individuals at a very low cost; however, many uninfected individuals are also receiving drugs. Fortunately, this poses no risk to them since the deworming medicines are extremely safe. Some researchers argue that mass deworming, in the absence of a positive test, does not improve nutrition, hemoglobin levels, school attendance, or academic performance. However, these results are derived from measuring mean improvements in the population receiving the intervention, which includes both infected and uninfected individuals. Obviously, no improvement should be expected in non-infected individuals that are treated only for logistic reasons. When health improvements are measured specifically in infected children, who are the targets of the intervention, the results indicate significant health benefits. The World Health Organization recommends mass treatments to all at-risk groups in endemic communities, especially women of childbearing age, and children. Mass treatments can also be provided to pregnant women in their second and third trimesters, and breastfeeding women. Every year over 400 million individuals are treated with this approach. For this purpose, broad-spectrum
benzimidazoles such as
mebendazole and
albendazole are the drugs of choice recommended by
WHO. These
anthelminthics are safe, inexpensive, and effective for several months. Mebendazole is given twice a day for three consecutive days, while albendazole is given as a single dose. WHO recommends annual treatment in areas where between 20 and 50% of people are infected, and a twice-a-year treatment if it is over 50%; and in low-risk situations (i.e. less than 20% prevalence) case-by-case treatment. In addition to these,
pyrantel pamoate is also equally effective on Ascaris. However, it has been reported that albendazole, mebendazole, and pyrantel pamoate are not entirely effective against
T. trichiura with single oral doses in population-based control.
Drugs for those with other diseases In cases of coinfection, combination therapy with
ivermectin and
diethylcarbamazine is advocated. However coinfection with
malaria and
HIV, especially among African women, does not respond well to the current combination therapies. It is more pressing for trichuriasis that the recommended drugs fail to provide positive results. A novel drug
tribendimidine, which was approved in China by the
CCDC for human use in 2004, has been subjected to
clinical trials showing that they are highly effective against major human
flukes, ascaris (>90% cure rate) and hookworm (>82%); however with low cure rate for whipworm (<37%).
Surgical intervention In some severe cases of ascariasis, the number of Ascaris worms can cause
intestinal obstruction requiring emergency surgery. ==Epidemiology==